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Abstract
Background
Perioperative myocardial injury (PMI) remains a major cause of perioperative morbidity
and mortality but clinical strategies to prevent PMI are still uncertain.
Methods and Results
We comprehensively searched PubMed for major research articles concerning clinical
strategies to prevent PMI. The key findings are as follows: (1) the American College of
Cardiology/American Heart Association guideline update for perioperative cardiovascular
evaluation for noncardiac surgery is very useful to stratify cardiac risk preoperatively; (2)
cardiac troponin has emerged as a biomarker to diagnose postoperative PMI and to predict
clinical outcomes; (3) coronary revascularization before noncardiac surgery probably
would provide cardiac protection in select patients, especially in patients with high-risk
coronary artery disease; (4) elective noncardiac surgery should be postponed in patients
who received coronary stenting recently because of high incidence of serious cardiac
complications (minimum 68 weeks for bare metal stents and 6-12 months for drug-eluting
stents); and (5) β-blockers and statins are very promising drugs and probably would
prevent PMI in a select patient population, especially in patients with intermediate risk
and stable coronary artery disease.
Conclusions
Further studies, especially randomized clinical trials and mechanistic investigation are

This paper has been peer reviewed. It is the authors’ final version prior to publication in The American Heart
Journal 154(6):1031-1028, December 2007. The published version is available at
http://dx.doi.org/10.1016/j.ahj.2007.07.025, copyright by Mosby, Inc.

needed to find the best and effective clinical strategies to prevent/reduce PMI. (Am
Heart J 2007;154:1021-8.)

Perioperative myocardial injury (PMI), including myocardial ischemia, cardiac
dysfunction, cardiac arrhythmias, myocardial infarction, and cardiac arrest continues to be
a major challenge to perioperative physicians because its incidence has not substantially
decreased for the past 2 decades.1,2 Despite extensive clinical and basic research, the
mechanisms responsible for PMI remain enigmatic. Currently, the predominant theories
are that PMI may be caused by prolonged stress- induced myocardial ischemia,
atherosclerotic plaque rupture, or a combination of the two. Clinically, perioperative
myocardial ischemia and infarction may present differently; pathologically, they are all
secondary to alterations of coronary plaque morphology and function and/or the loss of
balance between myocardial oxygen supply and demand, in which inflammation has been
linked with the development of atherosclerotic disease and instability and may cause acute
coronary syndromes (ACSs) and PMI.

The potential triggers for PMI include surgical stress, catecholamine release, and
inflammatory reaction; prolonged/repeated stress or extreme surgical stress especially may
inflict inflammation and induce repeated/prolonged myocardial ischemia, which may
serve as a primary cause for PMI, including perioperative myocardial infarction. Several
lines of evidence support this hypothesis. First, perioperative cardiac complications are
preceded almost universally by long-rather than short- duration ST-segment changes—an
indication of pro-longed myocardial ischemia.3,4 Second, most perioperative myocardial
infarctions occur early after surgery (most stressful time) and are asymptomatic (“silent”
myocardial infarction)5,6; most of them are preceded by episodes of increases in heart
rate4,6 and show non–Q wave rather than Q wave myocardial infarction,3,5 whereas
clinical studies have well demonstrated that complete coronary occlusion is infrequently
observed in patients with non–Q wave myocardial infarction (only 26%-42%) compared
with patients with Q wave infarction (≥84%).7 Third, β-adrenergic receptor blockers,
because of their inherent role of blocking sympathetic activation, have been shown to
reduce perioperative ischemia and the risk of myocardial infarction and death in high-risk
surgical patients (see below). Finally, our recent study demonstrated that chronic
catecholamine stimulation can aggravate myocardial injury by provoking inflammatory
reaction and increasing myocardial apoptosis, thereby illustrating a mechanistic link
between extreme/prolonged surgical stress → catecholamine release →
inflammation/myocardial apoptosis and PMI.8

Nevertheless, coronary plaque disruption was found in more than half of fatal
perioperative myocardial infarctions and was considered as a primary cause of fatal

9,10

perioperative myocardial infarction. More likely, surgery, especially major surgery with
its associated trauma, anesthesia, pain, bleeding, and hypothermia, is comparable to an
extreme stress test, thereby producing a triggering/provoking effect in the pathogenesis of
PMI (ie, inflicting inflammation and destabilizing plaques) and ultimately leading to
appearance of PMI.
11

Clinical strategies to prevent PMI have been evolving greatly. In 1977, Goldman et al
pioneered the concept of a risk index to account for the multifactorial nature of
contributors to risk of cardiac morbidity, which has led to the landmark development in
perioperative medicine, that is, the American College of Cardiology (ACC)/ American
Heart Association (AHA) guidelines for perioperative cardiovascular evaluation for
12
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noncardiac surgery in 1996 and an update in 2002. These guidelines focused on
preoperative testing to identify patients with significant coronary artery disease (CAD)
and subsequent coronary revascularization in select patients. The guidelines currently play
a major role in perioperative medicine. However, because of the poor positive predictive
value of noninvasive cardiac stress tests, the controversy about the benefit of coronary
revascularization before noncardiac surgery, and the considerable risk of coronary
angiography and coronary revascularization in high-risk patients, perioperative physicians
have been continuously searching for alternative approaches to prevent/reduce
14

perioperative cardiac complications. In 1996, Mangano et al performed a randomized
clinical trial (RCT) to investigate the effect of the β-blocker, atenolol, on patient outcomes
and concluded that in patients with risk for CAD who must undergo noncardiac surgery,
treatment with atenolol during hospitalization can reduce mortality and the incidence of
cardiovascular complications for as long as 2 years after surgery. In 2003, Poldermans et
15

al provided evidence in a case-controlled study that statin use reduces perioperative
mortality in patients undergoing major vascular surgery. More recently, the ACC/ AHA
16

updated their recommendations on perioperative βblocker therapy. These significant
developments in perioperative medical therapy to prevent/reduce PMI have shifted the
interest in perioperative cardiac care greatly, from risk stratification and potential coronary
revascularization to risk modification with β-blockers and/or statins. Nevertheless, the
debate and controversy exist in almost every aspect of clinical strategies to prevent PMI.
These strategies include mainly preoperative cardiac risk assessment, perioperative
monitoring, prophylactic coronary revascularization, coronary stents, and perioperative
medical therapy.

Preoperative cardiac risk assessment
The ACC/AHA guideline update for perioperative cardiovascular evaluation for
noncardiac surgery can help to stratify cardiac risk and identify the patients who need
13

preoperative interventions to reduce cardiac risk. The rationale for intensive screening is
based on the assumption that coronary revascularization prevents PMI in patients with
CAD. As the ACC/AHA task force stated in the guideline: “A large proportion of the data

used to develop these guidelines are based on observational or retrospective studies or
knowledge of management of cardiovascular disorders in the nonoperative setting.
Although the collective body of knowledge about the identification of high-and low-risk
patients by perioperative clinical and noninvasive evaluation is substantial, the number of
prospective or randomized studies that have been performed to establish the value of
13

different treatments on perioperative outcomes is small.” Based on the guidelines, many
patients undergo preoperative testing for detection of CAD before noncardiac surgery.
However, noninvasive cardiac stress testing for perioperative myocardial infarction or
death has very poor positive predictive values (b20%), although it has excellent negative
17

predictive values (near 100%). Therefore, there is uncertainty and much debate on how
to prepare surgery for the patient who has positive results from preoperative cardiac stress
testing, that is, medical therapy versus coronary revascularization. In addition, very few
RCTs support either of the treatments (see below).
18

The Lee et al revised cardiac risk index is a simple and practical clinical risk index. It
includes 6 variables to identify patients at high risk for perioperative cardiac
complications: history of CAD, history of congestive heart failure, history of cerebral
vascular accident, preoperative insulin treatment, serum creatinine level N2.0 mg/dL, and
high-risk surgical procedure. The presence of 3 or more of these risk variables (class III
and IV) conferred an event rate as high as 11% in a group of 1422 patients, whereas the
event rate was b1% in the presence of one or none of these variables (class I and II).

18

Other investigators also approached the problem of assessing PMI risk through the
development of multivariate models; they proposed that the expected risk from these risk
indices may vary along institutions

19

and a test required by these indices should only be
13

performed if this has consequences on perioperative management. And this is why
routine electrocardiogram and chest x-ray have been abandoned as preoperative tests in
low− and intermediate-risk surgical patients without specific indications.

Perioperative monitoring
Cardiac troponin I (cTnI) and cTnT have become the biomarkers of choice to diagnose
myocardial infarction and to risk-stratify patients with suspected ACS. A recent study by
20

Wong et al demonstrated that cTn elevations were associated with a higher risk of
multi-vessel disease, complex lesion morphology, and visible thrombus on coronary
angiography. Moreover, such patients had more impairment in microvascular function,
thereby suggesting a greater propensity for distal embolization of plaque material to the
microvasculature. Recently, intravascular ultrasound studies have illustrated that those
patients with ACS and elevated troponin levels had greater atheroma burden at the lesion
site, more reference segment atherosclerosis, and more frequent findings compatible with

21

thrombus at the lesion compared with patients who did not have troponin elevation.
Taken together, these findings likely explain the consistent association between troponin
elevation, even at low levels, and recurrent ischemic events in patients with ACS.
22
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In surgical patients, Landesberg et al and Kim et al have demonstrated that
postoperative cTn measurements can detect postoperative myocardial infarction and
predict short-term (6 months) and long-term (1-5 years) survival after vascular surgery.
Recently, in a study with intense postoperative cTnI surveillance in 1136 patients who
24

underwent abdominal aortic surgery, Le Manach et al revealed 2 types of PMI according
to the time of appearance and rate of increase in cTnI: acute (b24-hour) and early
increases of cTnI above threshold may indicate acute coronary occlusion for early
morbidity; prolonged low-level cTnI release followed by a delayed (N24 hours) increase
of cTnI may lead to prolonged myocardial ischemia for later events. They proposed
monitoring perioperative cTnI concentrations and early institution of treatment for patients
with increased cTnI before it leads to irreversible necrosis.
25

Recently, Mahla et al investigated the use of cardiac stress marker, N-terminal pro–brain
natriuretic peptide (NT-proBNP), to stratify PMI risk in patients undergoing vascular
surgery and found that a single postoperative NT-proBNP determination provides
important additional prognostic information for inhospital and late cardiac events and
therefore may support therapeutic decisions to prevent subsequent myocardial damage.
This study again provides evidence that the extent of surgical stress is closely related with
risk of PMI.
Despite the progress in clinical application of biomarkers for myocardial injury, such as
cTn as a marker of myocardial necrosis, there is still a lack of markers of myocardial
ischemia, especially the biomarkers that
(1) can detect myocardial ischemia without myocardial necrosis,
(2) increase the size of release proportional to the extent of ischemia,
(3) appear in circulation rapidly after onset of ischemia and last long enough for the
detection, and
(4) are easy to measure with high sensitivity and reasonable specificity.

Prophylactic coronary revascularization
The role of prophylactic/preoperative coronary revascularization in patients with CAD
before noncardiac surgery has been examined carefully in several clinical studies but
remains controversial. ACC/AHA guidelines update recommended coronary
revascularization only for subgroups of high-risk patients with unstable cardiac symptoms
or those for whom coronary artery revascularization offers a long-term benefit,
13

independent of the need for noncardiac surgery. This recommendation was based
26

predominately on the CASS as follows.

Coronary artery bypass graft before noncardiac surgery
In 1997, the CASS investigators reported their study, which is the largest study to date and
included 3368 noncardiac operations performed within a 10-year period among patients
assigned to medical therapy or coronary artery bypass graft (CABG). In this study they
found that among 1961 patients undergoing higher risk surgery (involving the thorax,
abdomen, vasculature, and head and neck), prior CABG was associated with fewer
postoperative deaths (1.7% vs 3.3%, P = .03) and myocardial infarctions (0.8% vs 2.7%, P
= .02) compared with medically managed CAD. There was no difference in the outcome
of patients undergoing low-risk procedures such as breast and urologic surgery. They
concluded that “in patients with known CAD, noncardiac surgeries involving the thorax,
abdomen, vasculature, and head and neck are associated with the highest cardiac risk,
26

which is reduced among patients with prior CABG.” However, major limitations of the
CASS are that the mortality and morbidity associated with CABG was not factored into
the analysis of perioperative outcomes and that perioperative medical treatments, such as
perioperative β-blocker and statin therapy, have undergone major improvements since the
study was published 10 years ago.
Coronary revascularization before vascular surgery
27

In the CARP trial, however, McFalls et al reported that patients with stable CAD who
were scheduled for elective vascular operations at 18 Veterans Affairs hospitals were
randomly assigned to undergo coronary revascularization (CABG or percutaneous
coronary intervention [PCI]) or medical therapy. After the vascular surgery, there were no
differences between the 2 groups in the incidence of myocardial infarction or mortality (a
median follow-up of 2.7 years), and therefore coronary revascularization by either CABG
or PCI before elective vascular surgery cannot be recommended in patients with stable
CAD. This randomized study provided evidence that coronary revascularization in
patients with stable CAD does not provide better protection when compared to current
medical therapy, which included β-blockers and statins. The study, however, excluded
patients with symptoms of unstable coronary disease, left main CAD, aortic stenosis, or
severe left ventricular dysfunction, which are class I indications for CABG based on
ACC/AHA guidelines for CABG surgery published in 1999.
26

28

29

30

In contrast, other studies by Eagle et al, Landersberg et al, and Garofalo et al have
shown that previous coronary revascularization provides protection against adverse
cardiac events and mortality after vascular surgery. The causes responsible for the
difference between the above studies are unclear but probably are due to patient
populations included in those studies being different. Taken together, for upcoming
surgery, patients with high-risk CAD (left main or 3-vessel disease, poor left ventricular
function, and/or diabetes) probably will benefit from coronary revascularization, whereas

patients with intermediate-risk and stable CAD will be more likely to do better with
optimal medical therapy.

13,26-30

CABG versus PCI (angioplasty or stenting) before vascular surgery
31

In the substudy of the CARP trial, Ward et al compared clinical outcomes in patients
receiving CABG versus PCI as prophylaxis for elective vascular surgery and found that
compared with patients with PCI (131 patients), patients with CABG (91 patients) had
fewer myocardial infarctions despite more diseased vessels in the CABG group and
tended to spend less time in the hospital after the vascular operation. The authors
concluded that more complete revascularization accounted for the intergroup differences.

CABG versus coronary angioplasty before noncardiac surgery
Previous studies have shown that CABG reduces the risk of cardiac complications after
noncardiac surgery. Whether coronary angioplasty provides equivalent protection is not
32

known. In BARI, Hassan et al found that rates of myocardial infarction and death after
noncardiac surgery are similarly low after contemporary bypass surgery or coronary
angioplasty in patients with multi-vessel CAD in a randomized study.

Coronary stents in surgical patients
Percutaneous transluminal coronary angioplasty (PTCA) was introduced by Gruntzing in
1977. Sigwart and Puel deployed the first coronary stent in humans in 1986. By 1999,
33

stenting or bare metal stents (BMSs) composed 84.2% of all PCIs. In 2001, the drugeluting stent (DES) was introduced and 2 years later it was approved by the Food and
34

Drug Administration in the United States. At present, most coronary stents have been
34

converted to DES in the United States. PTCA, coronary artery stent, and DES are 3
landmark developments in interventional cardiology. However, despite the initial
enthusiasm that resulted in the advent of DES, incomplete endothelialization and stent
thrombosis continue to plague these devices. Initial studies on animals demonstrated
complete endothelialization with BMS at 28 days, whereas DES uniformly showed
35

incomplete healing at 180 days.
36

In 2000, Kaluza et al first reported on 40 patients treated with BMS who underwent
noncardiac surgery within 6 weeks of stent implantation. Seven patients had myocardial
infarction, of which 6 were fatal. Other similar studies have also shown a high incidence
of cardiovascular complications when noncardiac surgery was performed shortly after
37,38

coronary stenting or PTCA alone.

The 2007 ACC/AHA for Cardiovascular Angiography and Interventions
recommendations for the prevention of stent thrombosis after coronary stent implantation
state that, at a minimum, patients should be treated with clopidogrel 75 mg and aspirin 325
mg for 1 month after BMS implantation, 3 months after sirolimus DES implantation, 6
months after paclitaxel DES implantation, and ideally, up to 12 months if they are not at
39

high risk for bleeding. This advisory stresses the importance of 12 months of dual
antiplatelet therapy after placement of a DES and educating the patient and health care
providers about hazards of premature discontinuation. It also recommends postponing
elective surgery for 1 year, and if surgery cannot be deferred, considering the continuation
of aspirin during the perioperative period in high-risk patients with DES. Nevertheless, in
40

a recent prospective observational study from 3 medical institutions, Vicenzi et al
reported that despite all patients receiving continuous heparin and antiplatelet drugs or
only shortly discontinued, nearly half of the patients (46 of 103, 44.7%) who received
coronary artery stents within 1 year had complications after surgery; 4.9% of the patients
died. All but 2 adverse events (bleeding only) were of a cardiac nature.

At present, for the patients with PCI who require surgery, there is still a lack of consensus
13

regarding how much time should pass between PCI and noncardiac surgery. However,
39

based on the ACC/ AHA recommendations as above, elective noncardiac surgery should
be postponed in patients who recently received coronary stenting for a probable minimum
of 6 to 8 weeks for BMS and 6 to 12 months for DES. More recently, based on a clinical
study in 60 patients, Ingraldi et al proposed that although DES is effective in keeping open
diseased heart arteries, they should not be used for patients who need to have noncardiac
surgery a short time after an interventional heart procedure; instead, BMS provides a safer
choice for these patients (abstract at the 2007 Scientific Session of the Society for
Cardiovascular Angiography and Interventions).

Perioperative medical therapy
In recent years, significant progress has been made in medical treatments of
cardiovascular diseases. Along with the progress, medical interventions with drugs such as
β-blockers and statins have been shown to reduce the occurrence of perioperative cardiac
complications, which has brought in the surge of interest on risk modification with
medical therapies instead of risk stratification with potential coronary revascularization in
surgical patients.
β-Blocker therapy
16

The ACC/AHA 2006 Guideline Update on Perioperative β-Blocker Therapy is a formal

position statement indicating that performance measures should be limited to class I or
class III recommendations—those recommendations in which patients should or should
not have the form of therapy—and that they should not include class IIa or IIb
recommendations, in which the evidence is less strong and for which opinion dictates the
class of indications. Class I recommendation includes the following: (1) β-blockers should
be continued in patients undergoing surgery who are receiving β-blockers to treat angina,
symptomatic arrhythmias, hypertension, or other ACC/AHA class I guideline indications;
(2) β-blockers should be given to patients undergoing vascular surgery at high cardiac risk
owing to the finding of ischemia on preoperative testing. Class III recommendation states
that β-blockers should not be given to patients undergoing surgery who have absolute
contra-indications to β-blockade.

The best protocol for administration of perioperative β-blockers remains uncertain,
although previous studies have demonstrated that tight heart rate control by β-blockers
41,42

reduced perioperative myocardial ischemia and improved clinical outcomes.
Statin therapy

Statin therapy is well established for prevention of cardiovascular disease. Statins may
also reduce postoperative mortality and morbidity via a pleiotropic (non– lipid-lowering)
43

effect. Recently, Hindler et al conducted a meta-analysis to evaluate the overall effect of
preoperative statin therapy on postoperative outcomes. They analyzed the data from 12
retrospective and 3 prospective trials with a total of 223 010 patients and found that
preoperative statin therapy was associated with 38% and 59% reduction in the risk of
mortality after cardiac and vascular surgery, respectively. When including noncardiac
surgery, a 44% reduction in mortality was observed.

Nevertheless, so far there is only one RCT on the effect of statin in patients undergoing
44

noncardiac surgery carried out in Brazil. In this study with 50 patients in the treatment
and 50 in the placebo group, respectively, short-term (45 days) treatment with atorvastatin
significantly reduced the incidence of major adverse cardiovascular events after vascular
surgery; that is, only 4 cases in the atorvastatin group had adverse events compared with
17 cases in the placebo group (8.0% vs 26.0%, P = .031). Despite the very positive
findings from this study, the trial was small and the treatment effect appears very large
(69% relative risk reduction), which is inconsistent with the results from other RCTs of
statins in preventing cardiovascular events.

α-2-Adrenergic agonist therapy
α-2-Adrenergic agonists, such as clonidine, can be used in those intolerant to β-blocker
therapy and have been shown to significantly reduce perioperative myocardial ischemia

45

and postoperative death.
Aspirin therapy

Aspirin, as an anti-inflammatory and antiplatelet medicine, has been widely used for longterm prevention of cardiovascular disease. However, in perioperative medicine, there are
still no data to support use of aspirin to prevent PMI. Periprocedural withdrawal of aspirin
may increase cardiovascular complications including ACS, but continuing aspirin
46

increases perioperative bleeding by about 1.5 fold. Preoperative and early postoperative
aspirin therapy has been reported to improve postoperative outcomes in patients
47,48

49

undergoing CABG.
In patients with vascular surgery, Robless et al conducted a metaanalysis of clinical trials of antiplatelet therapy and found that aspirin reduced the
incidence of myocardial infarction, stroke, and vascular death but the benefit did not reach
statistical significance. In contrast, in a large, multinational RCT on aspirin therapy as
prophylaxis for patients undergoing hip fracture surgery, ischemic cardiac events
(myocardial infarction or death) were found to be higher among patients who received
50

aspirin than placebo (hazard ratio 1.33, P = .05).

Despite the progress that has been made, several recent clinical trials (MaVS study,
52
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DIPOM trial, and POBBLE trial ) have failed to demonstrate the use of β-blockers in
the reduction of perioperative cardiac complications, and raised questions: Where did we
go wrong and shall we reverse the ACC/AHA recommendations on perioperative β54

55
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blockers? Further clinical trials (ie, POISE trial, and DECEASE-IV study ) are
ongoing, which may or may not clarify these controversies because the target population,
the choice of β-blockers, surgical procedures, and other options of the therapy may be
different. In addition, it should be appreciated that even superbly designed RCTs may be
inapplicable to large numbers of patients because the patients enrolled may not represent
the patient population or the patients excluded would normally receive the treatment of
interest. Nevertheless, those trials will certainly have important implications on whether or
how to give β blockers to perioperative patients.

In the broad field of clinical medicine, previous clinical trials have clearly demonstrated
that β-blockers provide multiple benefits to patients with CAD and heart failure, such as
decreasing mortality in patients with acute myocardial infarction, secondary prevention of
myocardial infarction in post–myocardial infarction patients, significant reduction in
arrhythmic death or cardiac death in post–myocardial infarction patients, and improving
57

survival in patients with heart failure. In a recent multinational cohort study that included
58

44372 patients with ACS in 14 countries, Fox et al demonstrated that improvements in
the management of patients with ACS, including increases in use of β-blockers, are
accountable for a significant decline in rates of new heart failure and mortality and in rates

of stroke and myocardial infarction at 6 months. In the field of surgery and
59

anesthesiology, Lindenauer et al conducted a very large retrospective cohort study
including 663635 patients from 329 hospitals throughout the United States. In this study,
they found that perioperative administration of β-blockers was associated with a reduced
risk of death in the hospital among high-risk, but not low-risk, patients undergoing major
noncardiac surgery, indicating a potential interaction between the effect of β-blockers and
the extent of CAD risk.

Because of the overwhelming number of studies, some with conflicting results, we
probably should consider the evidence in 2 dimensions, internal validity (RCTs) and
external validity (retrospective and/or observational studies), and recognize that different
methods may complement one another. Thus, the intervention adapted ideally should be
supported by evidence with both high internal and high external validity.

In summary, either β-blockers or prophylactic coronary revascularization more likely
would provide cardiac protection in select patient populations, that is, β-blockers for
patients with intermediate-risk and stable CAD, and prophylactic coronary
revascularization for patients with high risk of CAD. On the other hand, statins have
proven their therapeutic value for a wide range of patients with CAD; up to now, statins
have also appeared to provide cardiac protection for surgical patients. Nevertheless, given
that the present RCTs with statins in surgical patients is limited to one small trial in which
43,44

≤100 patients have actually been treated
and given that ACC/AHA/National Heart,
Lung, and Blood Institute clinical advisory on the use and safety of statins has concluded
that it may be prudent to withhold statins during hospitalization for major surgery because
60

of potential side effects such as myopathy, it is still premature to recommend the routine
use of statins for all surgical patients with cardiac risk.

Years have passed since the cardiac risk index was proposed in 1977; however, the PMI
conundrum continues. The pathogenetic mechanisms responsible for PMI remain a
mystery, which hinders us greatly from developing effective clinical strategies to
prevent/ reduce PMI.

We thank Drs. Grunwald and Seltzer for their critical review of the manuscript.
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